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Summary.-Subcellular fractions from an aminoazo dye induced rat hepatoma
(D23) were examined for their ability to evoke rejection responses in syngeneic
hosts to transplanted tumour cells and to induce the production of humoral antibody.
Membrane fractions isolated by zonal centrifugation and displaying an increased
activity of tumour specific antigen (Price and Baldwin, 1974), as well as crude mem-
brane fractions and purified tumour cell ghosts, all elicited tumour specific antibody
demonstrable by membrane immunofluorescence staining of viable hepatoma D23
cells. Tumour cell nuclei or soluble cytoplasmic protein were, however, lacking in
this capacity. Resistance to tumour cell challenge was not observed in rats treated
with any of the hepatoma D23 subcellular fractions administered by various routes
either alone or in admixture with bacterial adjuvants. These findings are relevant
to current views that tumour immunity may be more optimally achieved by inocula-
tion of intact (viable or attenuated) tumour cells.
IMMUNITY to transplanted tumours in
syngeneic hosts can be induced by prior
treatment of the recipients with tumour
cells prevented from progressive growth
(reviewed by Baldwin, 1973). This type
of immunization has frequently been
carried out using tumour cells attenuated
by radiation or treatment with cytotoxic
drugs, but a more effective response is
often achieved following exposure to
viable tumour cells. This was originally
demonstrated in studies showing the
development of tumour immunity follow-
ing surgical resection of tumour grafts
(Prehn and Main, 1957) and is further
emphasized by the expression of con-
comitant immunity in the tumour bearing
host (Baldwin, 1973). Also, it has been
shown that the tumour immune response
elicited with viable 3-methylcholanthrene
induced rat sarcoma cells in admixture
with B.C.G. is much greater than that
produced when radiation attenuated cells
are used (Baldwin and Pimm, 1973).
These approaches, however, impose serious
limitations in designing suitable protocols
forimmunotherapy since administration of
viable tumour cells, even in admixture
with bacterial adjuvants, may not be
acceptable and there are logistic problems
in the use of attenuated tumour cells.
From these considerations, it is clearly
desirable to employ cell-free tumour
antigen preparations and the studies
reported here were designed to examine
the immunogenicities ofisolated aminoazo
dye induced rat hepatoma membrane
fractions, isolated as described in the
previous paper (Price and Baldwin, 1974).
These fractions retain tumour specific
antigen, as defined by their capacity to
interact with tumour specific antibody
and, in this report, have been further
examined for their capacity both to induce
tumour rejection immunity as well as
specific humoral antibody responses.IMMUNOGENIC PROPERTIES OF RAT HEPATOMA SUBCELLULAR FRACTIONS 395
MATERIALS AND METHODS
Tumour and tumour cell fractionation.-
Details of the preparation of hepatoma D23
membrane fractions and nuclei are described
in the previous paper (Price and Baldwin,
1974).
Tumour cell ghost preparation.-Single
cell suspensions were prepared from minced
hepatoma D23 tissue by repeated treatment
with 0.25%o trypsin. Tumour cell ghosts
were isolated from cell suspensions after
stabilization of the cell surface with fluores-
cein mercuric acetate (Sigma Chemical Co.,
Kingston-upon-Thames, Surrey) according
to the method of Warren, Glick and Nass
(1966).
Preparation of soluble cytopla-smnic protein
(cell sap). Soluble fractions, remaining after
centrifugation of 1000 g supernatants at
78,000 g for 30 min, were dialysed for 4 h
against phosphate buffered saline, pH 7-3
(PBS), concentrated against Aquacide II
(Calbiochem) and redialysed against PBS for
a further 16 h. After centrifugation at
165,000 g for 30 min, the supernatant was
taken as the soluble cytoplasmic protein
(cell sap) fraction, and this was stored at
-200C.
Immunogenicity tests.-Syngeneic male
rats were immunized against various subcel-
lular fractions by 3 injections at weekly
intervals. Adjuvants were mixed at a
ratio of 1 :1 (v/v) with membrane suspen-
sions and 0-2 ml aliquots injected. Freund's
complete adjuvant (Difco, Detroit, Michigan)
was used and freeze dried B.C.G. (percutan-
eous) vaccine was supplied by Glaxo Labora-
tories Ltd (Greenford, Middlesex). Rats
were bled from the tail vein 6-10 days after
the final injection and serum samples col-
lected from individual rats were stored at
-20°C. Subcutaneous challenges withviable
hepatoma D23 cells suspended in medium
199 were administered 7-14 days following the
final injection of subeellular material.
The growth of tumours in immunized rats
was compared with that in untreated
controls receiving the same tumour cell
inoculum.
Membrane immunofluorescence tests.-The
membrane immunofluorescence test was per-
formed with viable hepatoma D23 cells in
suspension as previously described (Baldwin
and Barker, 1967).
Protein determination.-Protein concen-
tration was determined by the method of
Lowry et al. (1951).
RESULTS
Irnmunogenicity ofsubcellularfractions of
hepatoma D23
Representative tests performed to
evaluate the immunogenicity of isolated
membrane fractions of hepatoma D23
are summarized in Tables I and II. In
these tests, the effectiveness of subcellular
fractions in conferring transplantation
resistance to tumour cell challenge may
be compared with the protective effect
elicited by immunization with y irradiated
hepatoma D23 cells (Table I). Also,
in order to detect any low levels of resist-
ance, challenge doses of between 1 and
5 x 103 hepatoma cells were chosen since
these represent the minimum doses neces-
sary to produce consistent tumour growth
-in untreated control animals.
Immunization with the antigenic mem-
branes isolated by A-XII or B-XIV zonal
centrifugation of hepatoma D23 homo-
genates induced marked humoral anti-
body responses essentially comparable
with that obtained following immuniza-
tion with radiation attenuated tumour
cells (Table II). No protection, however,
was afforded to treated rats following
challenge with low doses of hepatoma
D23 cells (1-3 x 103 cells) and the out-
growth of tumours in immunized and
untreated rats was essentially equivalent
(Table I). Although the membranes in
these tests were isolated from the nuclear
sediment (1000 g pellets) of hepatoma
homogenates, purified nuclei lacked the
capacity to induce humoral antibody
formation and no significant protection
to tumour cell challenge was observed
in treated rats (Tables I and II).
Wolf and Avis (1970) have indicated
that the size of plasma membrane frag-
ments is critical in the induction ofimmu-
nity to a carcinogen induced murine
lymphoma and greatest protection against
viable tumour cell challenge was produced
by immunization with almost intact cell
ghost preparations rather than fragmentedM. R. PRICE AND R. W. BALDWIN
TABLE I.-Induction ofImmunity toTransplanted Hepatoma D23 byHepatoma
D23 Cells andSubcellularFractions
Tumour rejection tests
, s \~~
Immunizing
fraction
IR cells*
IR cells
A-zonal membrane
A-zonal membrane
B-zonal membrane
B-zonal membrane
Nuclei
Cell ghosts
Cell ghosts
Cell ghosts
Cell ghosts
ENMt
ENM+FCAt
EN[
ENM
ENM+FCA§
ENM+BCG§
ENM++BCG¶
ENM+FCA
ENM+BCG§
BCG§
ENM+BCGT
ENM+FCA
Soluble cell sap
Soluble cell sap
Total dose
(mg protein)
2 x 107 cells
1 X 107 cells
3-9 mg
27
- 0 mg
1*2 mg
6-3 mg
6 x 107 nuclei
3 - 0 x 106 ghosts
1 2 x 107 ghosts
3- 6 x 107 ghosts
6 - 9 x 107 ghosts
22-2 mg
22-2 mg
22-2 mg
22-2 mg
11-1 mg
11-1 mg
11-1 mg
11-1 mg
21-0 mg
21 0 mg
21 0 mg
42-0 mg
98-0 mg
Route of
immunization
i.p.
i.p.
s.c.
s.c.
s.c.
i.d.
s.c.
i.p
s.c.
s.c.
s.c.
i.d.
s.c.
footpad
s.c.
s.c.
s.c.
s.c.
s.c.
s.c.
s.c.
s.c.
s.c.
i.p.
i.p.
Tumour cell
challenge
(x 10-3)
50
500
2
3
1
1
1
5
2
2
2
1
1
1
1
1
1
1
1
1
1
1
1
1
1
Tumour takes in
Treated Untreated
0/4 4/4
1/4 4/4
5/5 5/5
5/5 4/4
5/5 5/5
5/5 5/5
4/5 5/5
5/5 6/6
5/5 5/5
4/5 5/5
5/5 5/5
5/5 5/5
5/5 5/5
5/5 5/5
5/5 5/5
5/5 5/5
4/5 5/5
4/5 5/5
5/5 5/5
5/5 5/5
5/5 5/5
5/5 5/5
5/5 5/5
4/5 5/5
4/5 5/5
* IR cells: Rats were immunized by 2 injections of y irradiated (15,000 rad) hepatoma D23 cells.
t ENM: Extranuclear membranes; in Experiments 12-19 ENM fractions were prepared by the method of Baldwin and Moore (1969) and in Experiments 20-23 ENM fractions were isolated as described by Price
and Baldwin (1974) using procedures developed for A-XII zonal centrifugation.
FCA: Freund's complete adjuvant.
§ Rats were pre-sensitized to the adjuvant by footpad injection 0 1 ml FCA or 0-1 ml FCA containing 0.5 mg moist weight of B.C.G. 10 days before the first injection. For immunization, membrane suspensions
were mixed at a ratio of 1: 1 with the sensitizing adjuvant.
O 5 mg moist weight ofB.C.G. in 0 1 ml FCA were injected in admixture with ENM suspensions.
TABLE II.-Hurnoral Antibody Response Evoked by Cells andSubcellular Fractions
ofHepatoma D23
Serum antibody*
Expt Immunizing Total dose Route of No. positive Fluorescence
No. fraction (mg protein) immunization No. tested index
1 IR cellst 2x 107 cells i.p. 4/4 0-34-0 55
2 IR cells 1 x 107 cells i.p. 2/4 0- 25-0* 38
3 A-zonal membrane 3.9 mg s.c. 5/5 0-45-0-55
4 A-zonal membrane 27 0 mg s.c. 5/5 0-51-0- 63
5 B-zonal membrane 1-2 mg s.c. 5/5 0-47-0-58
6 B-zonal membrane 6-3 mg i.d. 5/5 0-62-0-65
7 Nuclei 6x 107 nuclei s.c. 0/5 0 00-0 07
8 Cell ghosts 3* 0X 106 ghosts i.p. 4/5 0 24-0*55
12 ENM$ 22-2 mg i.d. 4/5 0-29-0-48
13 ENM+FCA 22-2 mg s.c. 5/5 0-32-0X46 14 ENM 22-2 mg footpad 4/5 0-29-0X51 15 ENM 22-2 mg s.c. 5/5 0-33-0 66
24 Soluble cell sap 42-0 mg i.p. 0/5 0-00-0-08
* Serum antibody was detected using the indirect membrane immunofluorescence test as described by Baldwin and Barker (1967). Serum fluorescence indices of 0*3 or greater represents a positive reaction. t IR cells: Rats were immunized by 2 injections of y irradiated (15,000 rad) hepatoma D23 cells. t ENM: Extranuclear membranes were prepared by the method of Baldwin and Moore (1969).
Expt
No.
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
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Fi. Hepatoma D23 cell ghosts, isolated by the methodl of Warren et al. (1966). Phase contrast
x 400.
surface membranes. In order to investi-
gate this, cell ghosts were prepared from
single cell suspensions of hepatoma D23
according to the method of Warren et al.
(1966) using fluorescein mercuric acetate
to stabilize the plasma membrane during
cell disruption. By phase contrast micro-
scopy, the membranes isolated using this
technique appeared as large empty bags
(Fig.) and often a lesion through which
the nucleus and cytoplasm were expelled
wasdistinguishable. AsindicatedinTable
I, immunization with up to 6 9 x 107
hepatoma D23 cell ghosts produced no
protection against challenge with 2 x 103
viable tumour cells. It is evident that
treatment of cell membranes with the
sulphydryl blocking reagent fluorescein
mercuric acetate did not grossly inactivate
hepatoma D23 specific antigen since
treated rats responded to immunization
by the production of significant levels of
humoral antibody detectable by mem-
brane immunofluorescence staining of
viable target cells (Table II).
In Experiments 12-23, the effects of
administration of the hepatoma D23
membranes by various routes and with or
without adjuvant were compared (Table I).
The membrane fractions used in these
tests were isolated as extranuclear mem-
branes (ENM) either following mechanical
homogenization of hepatoma D23 tissue,
as already described for the preparation
of tumour membranes by A-XII zonal
centrifugation (Price and Baldwin, 1974),
or by the method of Baldwin and Moore
(1969). The predominant response to
immunization by the intradermal, subcu-
taneous or footpad routes was again the
production ofhumoral antibody (Table II)
although treated rats showed no significant
resistance to challenge with viable hepa-
toma D23 cells (Table I). Comparably,
in Experiments 16-23, no protection to
tumour cell challenge was afforded to
rats treated with membrane fractions
administered in admixture with B.C.G.
or Freund's adju-vant. Prior sensitization
to B.C.G. by footpad injection (Experi-
ments 17 and 20) 10 days before immuni-
zation with the ENM fraction together
with B.C.G. was similarly ineffective in
promoting a turnour rejection responseM. R. PRICE AND R. W. BALDWIN
(Table I). The soluble cytoplasmic pro-
tein fraction which has been shown to be
lacking in tumour specific antigen (Bald-
win and Moore, 1969) failed to induce
significant tumour protection (Table I)
and also to elicit a humoral antibody
response demonstrable by the immuno-
fluorescence staining of hepatoma D23
target cells (Table II).
DISCUSSION
Immunization of syngeneic rats with
membrane preparations isolated from rat
hepatoma D23, as well as intact cell
ghosts consistently elicited tumour speci-
fic antibody, but treated rats were unable
to reject challenges with hepatoma D23
cells at a dose only just sufficient to
produce progressive growth in controls.
These findings are comparable with the
data already published on the immuno-
genicity of crude hepatoma membrane
fractions (Baldwin, Embleton and Moore,
1973b) where the principal response was
the development of humoral antibody,
with a weak cell mediated reaction, and
rats did not reject a subsequent challenge
with viable tumour cells. In the present
studies, subcellular fractions (nuclei and
soluble cytoplasmic protein) which are
considered to be lacking in hepatoma D23
specific antigen as assessed by in vitro
assay (Baldwin and Moore, 1969; Price
and Baldwin, 1974) did not elicit antibody
formation in treated rats, indicating that
these two methods for antigen detection
showed good correlation.
None of the variants introduced in the
present investigation, including the use
of membrane fractions with a higher
specific antigenic activity, or the incor-
poration of adjuvants such as B.C.G.,
modified the type ofimmune response and
the overall effect was essentially non-
protective against subsequent tumour
challenge. The lack of immunoprotection
by subcellular fractions in the rat hepa-
toma system contrasts with the resistance
conferred by subcellular materials demon-
strable with polycyclic hydrocarbon or
alkylnitrosamine induced tumours in the
mouse (Pilch, 1968; McCollester, 1970;
Wolf and Avis, 1970) and guinea-pig
(Oettgen et al., 1968; Holmes, Kahan and
Morton, 1970; Meltzer et al., 1972). In
these studies, membrane fractions (Pilch,
1968; McCollester, 1970; Wolf and Avis
1970) and solubilized membrane extracts
(Pilcb, 1968; Holmes et al., 1970; Meltzer
et al., 1972) as well as the soluble fraction
of tumour homogenates (Oettgen et al.,
1968) induced resistance to tumour cell
challenge although the significance of
these findings in relation to antigen
expression and the mechanism of host
immune responses remains to be defined.
The experiments in the rat hepatoma
system suggest that tumour antigen may
provoke atumourrejectiontype ofimmune
response only when expressed upon the
intact cell. This is supported by other
studies where the rejection oftransplanted
rat sarcomata can be induced by contra-
lateral administration of viable tumour
cells in admixture with B.C.G., but the
therapeutic response is considerably lower
whenradiation ormitomycin C-inactivated
cells are employed (Baldwin and Pimm,
1973; Baldwin and Cook, unpublished
findings). Of relevance to these findings,
Wagner (1973) demonstrated a relation-
ship between the immunogenicity of
living allogeneic cells and their active
metabolism as evaluated in an in vitro allo-
graft system. Mitomycin C, actinomycin
D or antimycin A treated cells were all
capable of inducing cytotoxic immune
responses in vitro although cells killed
by freeze-thawing or heating had almost
completely lost their immunogenicity.
These experiments were considered to
indicate that activation of cytotoxic T
cells to allogeneic cells may be mediated
via the release of soluble histocompati-
bility antigens at the cell surface.
It is evident that the role of subeel-
lular preparations in eliciting humoral
and cell mediated immune reactions in
vivo requires further evaluation. In this
respect, chemical modification of antigens
has been used to abrogate their ability
to evoke antibody mediated allergic
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responses in animals sensitized to the
unmodified antigen, while leaving the
cell mediated response intact (Parish,
1971a, b; Shirrmacher and Wigzell, 1972;
Thompson et al., 1972). However, in
attempting a similar manipulation of the
immune system, Levy et al. (1974)
observed that acetoacetylation of soluble
tumour extracts did not increase the
effectiveness of this material to protect
mice against subsequent challenge with
3-methylcholanthrene induced sarcoma
cells.
The predominant response to hepa-
toma membrane immunization is the
production ofhumoral antibody and other
studies have established that hepatoma
D23 antigen isolated as a soluble com-
ponent, either by enzymic digestion of
cell membranes (Baldwin and Glaves,
1972; Baldwin et al., 1974) orfrom tumour-
bearer serum (Baldwin et al., 1973a) also
induces tumour specific antibody without
the development of protection to tumour
cell challenge (unpublished findings).
These observations are relevant to the role
of circulating tumour antigen in the
tumour bearing host since humoral anti-
body responses to acellular tumour anti-
gens may modify tumour rejection re-
actions (Baldwin et al., 1973c). This has
already been demonstrated in experiments
where rats pre-immunized with membrane
fractions of hepatoma D23 failed to elicit
a tumour rejection reaction after treat-
ment with irradiated hepatoma D23 cells
(Baldwin et al., 1973b). This type of
observation may be comparable with
immunological enhancement phenomena
where prolonged survival of allografts
(Ranney et al., 1973; Sumerska et al.,
1974) or allogeneic tumour cells (Rosen-
berg et al., 1973) has been demonstrated
following pre-treatment with acellular
transplantation antigens.
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